Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Multicenter, Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas

NCT05580588 is registered in ClinicalTrials.gov with Shanghai Pharma Biotherapeutics USA Inc. as lead sponsor.

NCT NCT05580588
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05580588 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Multicenter, Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas
Lead sponsor
Shanghai Pharma Biotherapeutics USA Inc.
Phase
Phase 2
Overall status
Terminated
Start date
August 31, 2023
Completion date
October 31, 2024
Enrollment
14 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

liposarcoma, dedifferentiated